# 5 questions about the FDA's fast-track push for psychedelic treatments

- URL: https://theranews.net/blog/2026-04-25-5-questions-about-the-fdas-fast-track-push-for-psychedelic-treatments-e780ae/
- Published: 2026-04-25
- Type: Archive summary (AI-assisted summary of third-party reporting)
- Original outlet: washingtontimes
- Original report: https://www.washingtontimes.com/news/2026/apr/24/5-questions-fdas-fast-track-push-psychedelic-treatments/
- Topics: washington
- Publisher: TheraNews, operated by AdvancedCare USA Inc.
- Notice: Educational content, not medical, legal, billing or financial advice. Cite the original outlet, not this summary.

> The Food and Drug Administration awarded priority review vouchers to three companies developing psychedelic-based treatments for mental health conditions -- two studying psilocybin for hard-to-treat depression and one studying methylone, an MDMA-related drug, for PTSD.

---
![5 questions about the FDA's fast-track push for psychedelic treatments](/uploads/news-images/5-questions-about-the-fda-s-fast-track-push-for-ps-20260425230035.jpg)

---
*Originally reported by washingtontimes. [Read more](https://www.washingtontimes.com/news/2026/apr/24/5-questions-fdas-fast-track-push-psychedelic-treatments/)*

---

*Source: [https://www.washingtontimes.com/news/2026/apr/24/5-questions-fdas-fast-track-push-psychedelic-treatments/](https://www.washingtontimes.com/news/2026/apr/24/5-questions-fdas-fast-track-push-psychedelic-treatments/)*